Fox Run Management L.L.C. Raises Stake in Cellebrite DI Ltd. (NASDAQ:CLBT)

Fox Run Management L.L.C. boosted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 8.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 34,334 shares of the company’s stock after purchasing an additional 2,598 shares during the quarter. Fox Run Management L.L.C.’s holdings in Cellebrite DI were worth $756,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Quarry LP purchased a new position in shares of Cellebrite DI in the 3rd quarter valued at $27,000. Advisors Asset Management Inc. increased its holdings in Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after purchasing an additional 1,742 shares in the last quarter. R Squared Ltd purchased a new position in Cellebrite DI in the fourth quarter valued at about $100,000. Polen Capital Management LLC acquired a new position in shares of Cellebrite DI during the fourth quarter worth about $222,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Cellebrite DI in the fourth quarter worth about $234,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Stock Up 1.0 %

CLBT stock opened at $19.23 on Monday. The stock’s 50 day moving average is $21.12 and its two-hundred day moving average is $19.80. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The company has a market capitalization of $4.61 billion, a PE ratio of -13.83, a P/E/G ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on CLBT. JPMorgan Chase & Co. raised their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Lake Street Capital lifted their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Finally, Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of Cellebrite DI in a research note on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.